The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Coherus BioSciences
Stock and Other Ownership Interests - Coherus BioSciences
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Coherus Biosciences; Eisai; Exelixis; Genentech; Jazz Pharmaceuticals; Merck; Sumitomo Pharma Oncology; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst)
 
Kun-Ming Rau
No Relationships to Disclose
 
Ming-Lung Yu
Honoraria - Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics
Consulting or Advisory Role - Abbvie, BMS, Gilead, Roche and Roche diagnostics
Speakers' Bureau - Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics
Research Funding - Abbvie, BMS, Gilead, Merck and Roche diagnostics. (Inst)
Travel, Accommodations, Expenses - Abbott Laboratories
 
Hong Jae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BMS; Eisai; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER
Speakers' Bureau - AstraZeneca; Bayer; BMS; Dong-A ST; Eisai; Roche; Sanofi; SERVIER
Research Funding - BeiGene; Boryung (Inst); Dong-A ST (Inst); Hanmi; inno-n; Roche (Inst)
Travel, Accommodations, Expenses - Medivir (Inst)
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Stuart Roberts
Consulting or Advisory Role - AstraZeneca; Roche
 
Oxana Crysler
Research Funding - ACCRU (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Gina Vaccaro
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Incyte
Speakers' Bureau - Incyte
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); seagen (Inst); Surface Oncology (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst); XBiotech (Inst)
 
Hyung-Don Kim
Honoraria - AstraZeneca/MedImmune; Boostimmune; Boryung Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Mustbio
Research Funding - Roche/Genentech/Foundation Medicine
 
Koho Iizuka
No Relationships to Disclose
 
Hong Tang
Stock and Other Ownership Interests - Coherus Biosciences
 
Varun Kapoor
Employment - Coherus BioSciences
Stock and Other Ownership Interests - Coherus BioSciences
 
Daniel Chin
Employment - Coherus BioSciences
Stock and Other Ownership Interests - Coherus BioSciences
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
 
Yoon-Koo Kang
Consulting or Advisory Role - DAEHWA Pharmaceutical; HLB